PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.43 - 1.45
1.18 - 2.36
880.0K / 1.73M (Avg.)
-18.00 | -0.08
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
23.19%
Revenue growth above 1.5x 1177.HK's 1.79%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
-16.23%
Negative gross profit growth while 1177.HK is at 1.70%. Joel Greenblatt would examine cost competitiveness or demand decline.
-1724.67%
Negative EBIT growth while 1177.HK is at 13.37%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
2.41%
Operating income growth under 50% of 1177.HK's 16.17%. Michael Burry would be concerned about deeper cost or sales issues.
-2395.97%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-2389.16%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-2389.16%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.16%
Share change of 0.16% while 1177.HK is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.16%
Diluted share change of 0.16% while 1177.HK is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
27.59%
OCF growth of 27.59% while 1177.HK is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
20.17%
FCF growth of 20.17% while 1177.HK is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
-33.59%
Negative 10Y revenue/share CAGR while 1177.HK stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
64142.86%
5Y revenue/share CAGR above 1.5x 1177.HK's 131.22%. David Dodd would look for consistent product or market expansions fueling outperformance.
815.52%
3Y revenue/share CAGR above 1.5x 1177.HK's 64.03%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-121.97%
Negative 10Y OCF/share CAGR while 1177.HK stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-20.09%
Negative 5Y OCF/share CAGR while 1177.HK is at 155.61%. Joel Greenblatt would question the firm’s operational model or cost structure.
22.17%
3Y OCF/share CAGR under 50% of 1177.HK's 52.11%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-217.80%
Negative 10Y net income/share CAGR while 1177.HK is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-29.05%
Negative 5Y net income/share CAGR while 1177.HK is 115.75%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-22.71%
Negative 3Y CAGR while 1177.HK is 22.73%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
-47.75%
Negative 5Y equity/share growth while 1177.HK is at 469.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-26.24%
Negative 3Y equity/share growth while 1177.HK is at 269.07%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-100.00%
Cut dividends over 10 years while 1177.HK stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.73%
Inventory growth well above 1177.HK's 13.49%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
11.49%
Asset growth above 1.5x 1177.HK's 3.95%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-7.74%
We have a declining book value while 1177.HK shows 2.23%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
390.08%
We have some new debt while 1177.HK reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
306.60%
SG&A growth well above 1177.HK's 1.37%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.